DNA Damage Response Deficiency Assay predicts response to treatment in ovarian cancer

Ovarian cancer is the leading cause of death from gynaecological malignancies. The standard first line therapy is a combination of carboplatin and paclitaxel and has a response rate of 70%-80%, although the majority relapse. Almac have previously developed a 44 transcript DNA damage response deficiency (DDRD) assay which indicates loss of the FA/BRCA pathway and predicts response to DNA damaging agents.

In this study we have investigated the utility of the DDRD assay predicting response to platinum based therapy in ovarian cancer.

Click here to read more